1.	PharmacoEconomic Assessment IRESSA® in the Treatment of Non–Small-Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: 9461700718, NCT00173524
2.	Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913C00046, NCT00536107
3.	Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913L00071, NCT00770588
4.	Iressa Follow-up Trial Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0555, D7913L00008, NCT00357734
5.	Randomized Gefitinib Trial Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ONC-2008-001, NCT00807066
6.	Phase I/II Study of Gefitinib, Trastuzumab (Herceptin®), and Docetaxel in Patients With HER2/neu-Overexpressing Metastatic Adenocarcinoma of the Breast Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CHNMC-03049, IRB 03049, ZENECA-1839US/0274, ZENECA-IRUSIRES0012, NCT00086957
7.	A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NP01/07/03, NCT00212108
8.	Hydroxychloroquine and Gefitinib to Treat Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: NS 01/03/08, NCT00809237
9.	ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ID02-282, NCT00054691
10.	Phase II Pilot Study of Neoadjuvant Gefitinib in Patients With Resectable Stage I-IIIA Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MCC-13922, ZENECA-IRUSIRES0256, MCC-IRB-102794, NCT00104728
11.	Phase II Randomized Study of Whole-Brain Radiotherapy Combined With Either Gefitinib or Temozolomide in Patients With Non-Small Cell Lung Cancer and Brain Metastases Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SWS-SAKK-70/03, EU-20526, NCT00238251
12.	Phase II Study of Gefitinib in Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CASE-CCF-5538, ZENECA-1839IL/0234, NCT00268346
13.	JS 0414 A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0562, NCT00228501
14.	Post-Operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GORTEC 2004-02, NCT00169221
15.	Phase II Study of Neoadjuvant Paclitaxel, Cisplatin, Gefitinib, and Radiotherapy Followed by Surgery and Adjuvant Gefitinib in Patients With Resectable, Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: JHOC-J0386, J0386, JHOC-04-02-20-03, ZENECA-IRUSIRES0304, NCT00493025
16.	Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 13503A, NCT00519077
17.	Phase II Study of Neoadjuvant Gefitinib in Patients With Stage IIIA Nonsquamous Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: YONSEI-4-2006-0136, 4-2006-0136, ZENECA-YONSEI-4-2006-0136, NCT00616499
18.	Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 04-071, CA113653, NCT00588445
19.	ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: POCPZD, IRUSIRES0181, NCT00132158
20.	Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors Phase: Phase I Type: Supportive care, Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: ZD1839, NCT00186979
21.	ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 03C.225, NCT00328562
22.	Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FDCA001, NCT00497250
23.	A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NS01/19/05, NCT00717847